Chembio Diagnostics, Inc. (CEMI)

$0.86

+0.01 (+1.00%)
Rating:
Recommendation:
Neutral
Symbol CEMI
Price $0.86
Beta 1.645
Volume Avg. 0.83M
Market Cap 25.993M
Shares () -
52 Week Range 0.42-3.38
1y Target Est -
DCF Unlevered CEMI DCF ->
DCF Levered CEMI LDCF ->
ROE -112.19% Strong Sell
ROA -400.10% Strong Sell
Operating Margin -
Debt / Equity 181.62% Buy
P/E -
P/B 1.31 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CEMI news


Ms. Gail Page
Healthcare
Diagnostics & Research
NASDAQ Capital Market

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.